Evotec SE completed a public share offering on the US Nasdaq market on 9 November, raising a total of $435 million from the base offering and giving it more resources to pursue a strategy as development partner for the global biopharma industry. The share offering came after a third quarter during which revenue increased by 23% to €159.7 million on the strength of ongoing partnerships with large pharma companies.
